## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Confirmation No. 2862

Akira NISHIYAMA et al.

Docket No. 2001\_1748A

Serial No. 09/990,389

Group Art Unit 1623

Filed November 23, 2001

PHENOXYPROPYLAMINE COMPOUNDS

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents, Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 is enclosed.

[X] This Information Disclosure Statement is submitted: la.

within three months of the filing date (or of entry into the National Stage) of the aboveentitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

[] This Information Disclosure Statement is submitted 1b.

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) [] the certification of paragraph 2 below is provided, or

	(2) [] the	fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.						
1c.	[] This Information Disclosure Statement is submitted:							
	after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:							
	the certi	the certification of paragraph 2 below is provided, and						
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.								
2.	It is here	It is hereby certified						
	a. []	that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or						
	b. []	that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.						
3. []	Conside abandor	eration of the following list of additional information (including any copending or ned U.S. application, prior uses and/or sales, etc.) is requested.						
4.	For eac	h non-English language reference listed on the attached form PTO-1449, reference is						
	a. []	a full or partial English language translation submitted herewith,						
	b. [X]	a foreign patent office search report (in the English language) of record,						
	c. []	the concise explanation contained in the specification of the present application at page,						
		- 2 -						

- d. [X] the concise explanation set forth in the attached English language abstract,
- e. [X] the concise explanation set forth below or on a separate sheet attached to the reference:

The JP '175 reference corresponds to the EP '133 reference; the JP '877 reference corresponds to the WO '249 reference; the JP '270 reference corresponds to the WO '842 reference; the JP '183 reference corresponds to the US '439 reference; the JP '872 reference corresponds to the EP '331 reference; the JP '361 reference corresponds to the WO '152 reference; the JP '827 reference corresponds to the US '765 reference; the JP '880 reference corresponds to the US '793 reference; the JP '228 reference corresponds to the US '431 reference; the JP '307 and JP '610 references correspond to DE 2,702,919 for which an English abstract is submitted herewith; the JP '538 reference corresponds to US '760 reference.

5. [X] A foreign patent office search report (International Search Report) citing one or more of the references of record.

Respectfully submitted,

Akira NISHIYAMA et al.

Michael R. Davis

Registration No. 25,134 Attorney for Applicants

MRD/aeh Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 February 25, 2002 Sheet 1 of 3 SERIAL NO. ATTY DOCKET NO. FORM PTO 1449 (modified) 09/990,389 2001\_1748A U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE APPLICANT Akira NISHIYAMA et al. LIST OF REFERENCES CITED BY APPLICANT(S) GROUP (Use several sheets if necessary) FILING DATE 1623 November 23, 2001 Date Submitted to PTO: February 25, 2002 U.S. PATENT DOCUMENTS **FILING DATE IF** SUBCLASS **CLASS** NAME DATE DOCUMENT APPROPRIATE \*EXAMINER NUMBER INITIAL Abraham et al. 7/1995 5,436,337 AA Press et al. 8/1989 4,861,897 AB Kampfer et al. 6/1974 3,816,131 AC Witte et al. 6/1987 4,670,439 ΑD Fritsch et al. 3/1980 ΑE 4,191,765 12/1975 Popelak et al. 3,929,793 AF Audia et al. 3/1996 AG 5,500,431 Kampfer et al. 5/1974 3,810,760 AΗ FOREIGN PATENT DOCUMENTS TRANSLATION SUBCLASS **CLASS** COUNTRY DATE DOCUMENT YES NUMBER JP 7-17952 1/1995 ΑI JP 6/1999 11-158175 AJ EP 3/1999 0 905 133 ΑK JP 5/1997 9-136877 AL. wo 1/1997 97/00249 AM JP 9/1993 8-508270 ΑN WO 94/22842 10/1994 AO wo 10/1992 92/18089 AP JP 9/1986 61-218582 ΩA JP 3/1986 61-43183 AR JP 10/1985 60-202872 AS EP 0 156 331 10/1985 AT DATE CONSIDERED **EXAMINER** 

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3  FORM PTO 1449 (modified)				ATTY DOCKET NO. 2001_1748A		SERIAL NO. 09/990,389				
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			CE	APPLICANT						
			Ī	Akira NISHIYAMA et al.  FILING DATE November 23, 2001			GROUP 1623			
Date Submit		PTO: February 25,		November 23, 2001			1		:	
T	<del>- T</del>	DOCUMENT		FOREIGN PATENT DOCUMENTS  COUNTRY	CLA	ASS	SUBCLASS		TRANSLATION	
		DOCUMENT NUMBER	DATE		<u> </u>		-	YES		
	ВА	80/00152	2/1980	wo						
	ВВ	53-12827	2/1978	JP						
	вс	50-41880	4/1975	JP				-		
	BD	8-509228	10/1996	JP						
	BE	61-057572	3/1986	JP	<u></u>					
	BF	95/24200	9/1995	wo						
	BG	58-121214	7/1983	JP					1	
	вн	55-100361	7/1980	JP						
	ВІ	52-90307	7/1977	JP						
	BJ	52-92610	8/1977	JP				,		
	вк	47-18538	9/1972	JP			1			
	BL	99/55672	11/1999	wo			1			
	ВМ	2000-86603	3/2000	JP						
	BN	00/37464	6/2000	wo						
				S) (Including Author, Title, Date, Pe						
	во	Zawadowski, T	Γ., et al. "SYN" YM DZIAŁANII	NTEZA NOWYCH, AMINOALI IU β-ADRENOLITYCZNYM", A cal abstract thereof.	KANOLO	OWYCH	H POCHODNYCH	H BENZOFL vol. 46, no	JRANU O 3 (1989)	
	ВР	Besenfelder, E. "High Performance Liquid Chromatographic Determination of Picumast and two Active Metabolites in Plasma using On-line Sample Preparation", Biomedical Chromatography, vol. 5 (1997), pages 32-37; with chemical abstract thereof.								
	BQ	Covello, M., et al. "Nuovi iodorganici di sintesi lodobenzalidantoine e iodobenzaltioidantoine", Rend. Accad. Sci. Fis. Mal., vol. 35 (1968), pages 156-164; with chemical abstract thereof.								
	BR	Meltzer, R.I., et al. "Reaction of 4-Hydroxy-3,5-diiodophenylpyruvic Acid with 3,5-Diiodotyrosine", J. Org. Chem., vol 26 (1961), pages 1977-1979; with chemical abstract thereof.								
PVALMIET	<u> </u>			DATE CONSID	DERED					
EXAMINER				DATE CONSIL	DERED					

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		i i					
Sheet 3 of 3			· · · · · · · · · · · · · · · · · · ·		ι		
FORM PTO 1449 (modifi			2001_1748		SERIAL NO. 09/990,389		
PATENT A	AND 1	MENT OF COMMERCE TRADEMARK OFFICE S CITED BY APPLICANT(S)	APPLICANT Akira NISHIYAMA et al.				
(Use several sheets if necessary)  Date Submitted to PTO: February 25, 2002			FILING DATE November 2:	3, 2001		GROUP 1623	
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
C	CA	Katsumi, I., et al. "Studies on Styrene Derivatives. I. Synthesis and Antiinflammatory Activities of α-Benzylidene-γ-butyrolactone Derivatives", Chem. Pharm. Bull., vol. 34, no. 1 (1986), pages 121-129.					
С	СВ	Shiba, T., et al. "Synthesis of Specifically Iodine-131- and Carbon-14-Labeled Thyroxine", J. Org. Chem., vol. 27 (1962), pages 1773-1778; with chemical abstract thereof.					
С	СС	Bharathi, K., et al. "Synthesis, Pharmacological Evaluation and QSAR Studies of 4,5-Dihydro-4-[(substituted Phenyl) Methylene]-5-oxo-2-Phenyl/methyl-1H-Imidazole-1-Acetic Acids", Indian Journal of Pharmaceutical Sciences, vol. 61, no. 3 (1999), pages 186-189.					
EXAMINER DATE CONSIDERED							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.